Ovarian Cancer Clinical Trial
Official title:
The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Epithelial Ovarian Cancer
44 patients were enrolled in this study as they had malignant epithelial ovarian tumor.Pre-operative staging was assessed by CT scan based on FIGO classification and compared to the standard laparotomy surgical staging. Maximal surgical effort for Optimum cytoreduction was achieved and the risk factors for sub-optimal cytoreduction were studied
Each patient was subjected to comprehensive medical history taking and careful clinical
examination, laboratory investigations (CA-125) and imaging (abdomino-pelvic CT scan).
Patients with suspected bowel involvement were subjected for colonoscopy.
Pre-operative Abdomino-pelvic CT scans:
Preoperative CT scans were performed with a high-speed scanner after the oral and
intravenous administration of contrast medium. The hard copy images were reviewed by
consultant radiologists for assessment of the findings suggestive of malignant adnexal mass
which are bilateral lesions, thick septa, enhancing solid components, ascites, and
peritoneal deposits .
Pre-operative staging of cancer ovary was assessed by CT scan based on FIGO classification:
1. Stage II: tumor involving ovaries with pelvic extension +/- ascites.
2. Stage III: tumor involving ovaries with peritoneal implant outside pelvis +/- ascites.
3. Stage IV: tumor involving ovaries with parenchymal liver metastasis and/or pleural
effusion.
Surgical treatment:
All patients underwent standard longitudinal laparotomy, intensive surgical staging and
maximal surgical effort for Optimum cytoreduction which was included all of the following
(total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic-omentectomy,
appendectomy, surgical removal of all tumor masses, intestinal resections if
required).Achievement of no gross residual disease has been attempted in all cases. Finally,
patients were divided into two groups:
- Suboptimal cytoreduction group with any gross tumor residue.
- Optimal cytoreduction group without any gross tumor residue.
Surgical risk factors for optimum cytoreduction:
- Parenchymal liver involvement.
- Omental involvement.
- Bowel involvement.
- Para aortic lymph node involvement.
- Peritoneal carcinomatosis: it is defined as disease > 4 mm involving 2 or more of the
following areas; lateral colic gutters, anterior abdominal wall, diaphragm, and pelvic
peritoneal reflections.
- Pelvic sidewall invasion: it is defined as presence of one or more of the following;
tumor fixed to the pelvic bony wall, encasement of iliac vessels, and hydroureter.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |